Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Jun;36(6):853-8.
doi: 10.1002/hed.23384. Epub 2013 Oct 4.

Intraoperative near-infrared fluorescence imaging of parathyroid adenomas with use of low-dose methylene blue

Affiliations

Intraoperative near-infrared fluorescence imaging of parathyroid adenomas with use of low-dose methylene blue

Joost R van der Vorst et al. Head Neck. 2014 Jun.

Abstract

Background: Intraoperative identification of parathyroid adenomas can be challenging. We hypothesized that low-doses methylene blue (MB) and near-infrared fluorescence (NIRF) imaging could be used to identify parathyroid adenomas intraoperatively.

Methods: MB was injected intravenously after exploration at a dose of 0.5 mg/kg into 12 patients who underwent parathyroid surgery. NIRF imaging was performed using the Mini-FLARE imaging system.

Results: In 10 of 12 patients, histology confirmed a parathyroid adenoma. In 9 of these patients, NIRF could clearly identify the parathyroid adenoma during surgery. Seven of these 9 patients had a positive preoperative (99m) Tc-sestamibi single photon emission CT (SPECT) scan. Importantly, in 2 patients, parathyroid adenomas could be identified only using NIRF.

Conclusion: This is the first study to show that low-dose MB can be used as NIRF tracer for identification of parathyroid adenomas, and suggests a correlation with preoperative (99m) Tc-sestamibi SPECT scanning.

Keywords: hyperparathyroidism; image-guided surgery; methylene blue; near-infrared fluorescence imaging; parathyroid adenoma.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST STATEMENT

Joost R. van der Vorst, M.D.: Nothing to declare

Boudewijn E. Schaafsma, M.D.: Nothing to declare

Floris P.R. Verbeek: Nothing to declare

Rutger-Jan Swijnenburg, M.D., Ph.D.: Nothing to declare

Quirijn Tummers, M.D.: Nothing to declare

Merlijn Hutteman, Ph.D.: Nothing to declare

Jaap F. Hamming, M.D., Ph.D.: Nothing to declare

Cornelis J.H. van de Velde, M.D., Ph.D.: Nothing to declare

J. Kievit, M.D., Ph.D.: Nothing to declare

FLARE technology is owned by Beth Israel Deaconess Medical Center, a teaching hospital of Harvard Medical School. It has been licensed to the FLARE Foundation, a non-profit organization focused on promoting the dissemination of medical imaging technology for research and clinical use. Dr. Frangioni is the founder and chairman of the FLARE Foundation. The Beth Israel Deaconess Medical Center will receive royalties for sale of FLARE Technology. Dr. Frangioni has elected to surrender post-market royalties to which he would otherwise be entitled as inventor, and has elected to donate pre-market proceeds to the FLARE Foundation.

Alexander L. Vahrmeijer, M.D., Ph.D.: Nothing to declare

Figures

Figure 1
Figure 1. Preoperative surgical planning and intraoperative NIR fluorescence-guided resection of a parathyroid adenoma located in the neck
A: 3D SPECT-CT image 2 h postinjection of 99mTc-sestamibi with visualization of a parathyroid adenoma located at the right side of the neck (arrow). B: During minimally-invasive parathyroid surgery, a parathyroid adenoma is identified using NIR fluorescence imaging, 5 and 10 minutes postinjection of 0.5 mg/kg MB. T= thyroid tissue.
Figure 2
Figure 2. Preoperative surgical planning and intraoperative NIR fluorescence-guided resection of a parathyroid adenoma located in the mediastinum
A: 3D SPECT-CT image 2 h postinjection of 99mTc-sestamibi with visualization of a parathyroid adenoma located paratracheally in the mediastinum (arrow). B: A parathyroid adenoma located paratracheally in the mediastinum is identified using NIR fluorescence imaging, 10 minutes postinjection of 0.5 mg/kg MB.
Figure 3
Figure 3. Schematic overview of parathyroid adenoma location and corresponding detection methods
Shown is the location of all parathyroid adenomas (N = 10) and one parathyroid carcinoma (N = 1, Asterix) and corresponding imaging modalities with which they were identified. The patient with parathyromatosis was excluded from this scheme.
Figure 4
Figure 4. Histopathological evaluation and fluorescence microscopy
Shown are 40X H&E staining (left) of the resected specimen, which shows oncocytic cells with monotone round nuclei surrounding a blood vessel. The right image shows the same section stained with 4′,6-diamidino-2-phenylindole (DAPI) nuclear staining (blue), with the 700 nm NIR fluorescence from MB pseudo-colored in yellow. The NIR fluorescent signal is located in the oncocytic cells.

Similar articles

Cited by

References

    1. Udelsman R. Six hundred fifty-six consecutive explorations for primary hyperparathyroidism. Ann Surg. 2002;235:665–670. - PMC - PubMed
    1. Grant CS, Thompson G, Farley D, et al. Primary hyperparathyroidism surgical management since the introduction of minimally invasive parathyroidectomy: Mayo Clinic experience. Arch Surg. 2005;140:472–478. - PubMed
    1. Lew JI, Solorzano CC. Surgical management of primary hyperparathyroidism: state of the art. Surg Clin North Am. 2009;89:1205–1225. - PubMed
    1. Norman J, Lopez J, Politz D. Abandoning unilateral parathyroidectomy: why we reversed our position after 15,000 parathyroid operations. J Am Coll Surg. 2012;214:260–269. - PubMed
    1. Patel CN, Salahudeen HM, Lansdown M, et al. Clinical utility of ultrasound and 99mTc sestamibi SPECT/CT for preoperative localization of parathyroid adenoma in patients with primary hyperparathyroidism. Clin Radiol. 2010;65:278–287. - PubMed

Publication types

MeSH terms